ALNY Financial Facts

Unrealized (loss) gain on marketable securities: -18.33M
Total other income (expense): 2.32M
See Full Income Statement

Total liabilities and stockholders' equity: 1.38B
Additional paid-in capital: 2.57B
See Full Balance Sheet

Alnylam Pharmaceuticals, Inc. (ALNY) Earnings

  |   Expand Research on ALNY
Next EPS Date 8/3/22 *Est. EPS Growth Rate +9.1% *Last Qtr.
Average EPS % Beat Rate +5.0% Revenue Growth Rate +20.1% *Last Qtr.
Average % Move 1-Wk after EPS -0.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/28/22 Q122 -$1.49-$1.84 +$0.35$213.26M$243.02M N/A Details
2/10/22 Q421 -$1.69-$1.56 -$0.13$258.5M$231.44M N/A Details
10/28/21 Q321 -$1.72-$1.57 -$0.15$187.6M$218.54M N/A Details
8/3/21 Q221 -$1.30-$1.60 +$0.30$220.1M$193.18M N/A Details
4/29/21 Q121 -$1.64-$1.75 +$0.11$177.6M$168.74M N/A Details
2/11/21 Q420 -$1.60-$1.76 +$0.16$163.6M$146.07M N/A Details
11/5/20 Q320 -$1.58-$1.66 +$0.08$125.9M$120.75M N/A Details
8/6/20 Q220 -$1.67-$1.74 +$0.07$104M$99.48M N/A Details